Amplatzer
closure devices allow nonsurgical closure of cardiac septal defects
in children and adults
A high-technology titanium device with a long record of use in Europe
is gaining wider use in the United States. The product, called an
Amplatzer closure device, can be implanted nonsurgically in both children
and adults, representing a major advance in repair of congenital cardiac
septal defects.
Cardiologists at Cedars-Sinai
Medical Center have implanted roughly two dozen devices in children
and adults since the closure device was approved by the FDA for
use early in 2002. Instead of the previously necessary open-heart
surgery, adults can now enter the catheterization laboratory and
have the device implanted with a procedure lasting about 30-35 minutes.
Only a local anesthetic is required, and the patient can be discharged
the same day.
In the case of young children,
such as a 6-year-old girl with a congenital atrial septal defect,
the procedure was done under a general anesthetic but still required
only about 60-90 minutes rather than the 3 hours of open heart surgery.
L. Stephen Gordon, M.D., pediatric cardiologist, explained that
he chose the appropriate size device only after angiography had
visualized her heart and the closure device and he had measured
the pressure and oxygen content in each chamber and measured the
size of the defect itself.
The device itself is made of
a nickel-and-titanium alloy. It was attached to a tiny cable that
was threaded through the catheter to the site of the defect. At
that point, he pushed the closure device out of the catheter and
into the defect, positioning it centrally in the hole, so that the
two disks of the closure device rested on each side of the hole.
After confirming the positioning of the device, the cardiologist
released it by unscrewing the cable that had been used to slide
it through the catheter.
|